New drug HT31-1 takes first step: safety check in healthy volunteers
NCT ID NCT07449572
First seen Mar 09, 2026 · Last updated May 21, 2026 · Updated 9 times
Summary
This early-stage study tests the safety of a new drug called HT31-1 in 24 healthy adults aged 18-65. The drug is being developed to treat acute respiratory distress syndrome (ARDS), a severe lung condition. Participants receive a single dose and are monitored for side effects. This study does not offer treatment for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University (VCU Health)
Richmond, Virginia, 23298, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.